Main achievements of low-dose computed tomography in lung cancer screening
https://doi.org/10.21292/2075-1230-2021-99-1-61-70
Abstract
The objective of the study: to summarize current data on the use of low-dose computed tomography (LDCT) for lung cancer screening (LCS).
Subjects and methods: Relevant articles published from 2016 to 2019 were searched for the following key words: lung cancer screening, low-dose computed tomography, ultra-low-dose computed tomography. The search was performed in the open databases of PubMed, Google Scholar, Elibrary. 23 Russian and 778 English publications were found. Among them, relevant publications with high citation indices were selected.
Results. By 2019, there have been significant changes in the methodology of LDCT in LCS, and these changes can be considered as one of the priority state areas of modern health care. The article considers the main and potential additional goals of screening for lung cancer, the parameters of inclusion into lung cancer risk groups according to the data of various global studies. It describes data on the recommended maximum permissible doses of radiation exposure in different countries and the economic efficiency of screening. In addition, the technical requirements for a computed tomography scanner in LCS and methods for interpreting LDCT have been systematized.
About the Authors
V. A. Gombolevskiy
Scientific Practical Clinical Center of Diagnostics and Telemedicine Technologies, Moscow Health Department
Russian Federation
Russian Federation
Viktor A. Gombolevskiy - Candidate of Medical Sciences, Head of Department for Radiology Quality Enhancement.
28, Bd. 1, Srednaya Kalitnikovskaya St., Moscow, 109029, Phone: +7 (495) 670-74-80
V. Yu. Chernina
Scientific Practical Clinical Center of Diagnostics and Telemedicine Technologies, Moscow Health Department
Russian Federation
Russian Federation
Valeriya Yu. Chernina - Junior Researcher of Department for Radiology Quality Enhancement.
28, Bd. 1, Srednaya Kalitnikovskaya St., Moscow, 109029, Phone: +7 (495) 670-74-80
I. A. Blokhin
Scientific Practical Clinical Center of Diagnostics and Telemedicine Technologies, Moscow Health Department
Russian Federation
Russian Federation
Ivan A. Blokhin - Junior Researcher of Department for Radiology Quality Enhancement.
28, Bd. 1, Srednaya Kalitnikovskaya St., Moscow, 109029, Phone: +7 (495) 670-74-80
A. E. Nikolaev
Scientific Practical Clinical Center of Diagnostics and Telemedicine Technologies, Moscow Health Department
Russian Federation
Russian Federation
Aleksandr E. Nikolaev - Junior Researcher of Department for Radiology Quality Enhancement.
28, Bd. 1, Srednaya Kalitnikovskaya St., Moscow, 109029, Phone: +7 (495) 670-74-80
A. A. Barchuk
Petrov National Medical Research Center of Oncology
Russian Federation
Russian Federation
Anton A. Barchuk - Researcher.
68, Leningradskaya St., Settlement of Pesochny, St. Petersburg, 197758, Phone: +7 (812) 439-95-54S. P. Morozov
Scientific Practical Clinical Center of Diagnostics and Telemedicine Technologies, Moscow Health Department
Russian Federation
Russian Federation
Sergey P. Morozov - Doctor of Medical Sciences, Professor, Director.
28, Bd. 1, Srednaya Kalitnikovskaya St., Moscow, 109029, Phone: +7 (495) 678-54-95References
1. Avksentieva M.V et al. Assessment of the social economic burden of lung cancer in the Russian Federation. Meditsinskiye Tekhnologii. Otsenka i Vybor, 2018, no. 4 (34). (In Russ.)
2. Gombolevskiy VA. et al. The low-dose computed tomography protocol for Hodgkin's lymphoma. Vestnik Rossiyskogo Nauchnogo Tsentra Rentgenoradiologii Minzdrava Rossii, 2013, vol. 3, no. 13. (In Russ.)
3. Gombolevskiy V.A. et al. Organization and efficiency of screening for malignant lung tumors by low-dose computed tomography. Radiologiya-Praktika, 2018, no. 1, pp. 28-36. (In Russ.)
4. Gusamova N.V. et al. Lung cancer screening by LDCT. Results for 2015-2017 by Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky. Sovremennyye dostizheniya onkologii v klinicheskoy praktike: materialy Vserossiyskoy nauchno-prakticheskoy konferentsii. [Contemporary achievements of oncology in clinical practice. Abst. Book of the All-Russian scientific and practical conference]. RPF SMiK Publ., Krasnoyarsk, 2017, pp. 210. (In Russ.)
5. Gusev K.V. et al. Experience of using low-dose computed tomography for early detection of lung cancer in the population of Tyumen Region. Akademicheskiy Journal Zapadnoy Sibiri, 2018, vol. 14, no. 5, pp. 26. (In Russ.)
6. Egorova A.G., Orlov A.E. The main components of the concept for development and improvement of the oncological services of Samara Region. Informatsionnyye Tekhnologii v Meditsine i Farmakologii, 2015, pp. 50-53. (In Russ.)
7. Morozov S.P. et al. Artificial intelligence: automated natural language text analysis for radiological examination audits. Vestnik Rentgenologii i Radiologii, 2018, vol. 99, no. 5, pp. 253-258. (In Russ.)
8. Morozov S.P. et al. Low-dose computed tomography in Moscow for lung cancer screening (LDCT-MLCS): baseline results. Voprosy Onkologii, 2019, vol. 65, no. 2, pp. 224-233. (In Russ.)
9. Nikolaev A.E. et al. Incidental findings during lung cancer screening by low-dose computed tomography. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 11, pp. 60-67. (In Russ.)
10. Osnovnyye sanitarnyye pravila obespecheniya radiatsionnoy bezopasnosti OSPORB-99/2010. SP 2.6.1.2612-10. [Basic sanitary rules for ensuring radiation safety OSPORB-99/2010. SP 2.6.1.2612-10].
11. Recommendations for early diagnosis of lung cancer for primary care physicians. Vestnik Rentgenologii i Radiologii, 2016, vol. 97, no. 2, pp. 69-78. (In Russ.)
12. Rukovodstvo po ranney diagnostike raka. [Guide to cancer early diagnosis]. Geneva, World Health Organisation, 2018. License: CC BY-NC-SA 3.0 IGO.
13. SanPiN 2.6.1.1192-03 Gigiyenicheskiye trebovaniya k ustroystvu i ekspluatatsii rentgenovskikh kabinetov, apparatov i provedeniyu rentgenologicheskikh issledovaniy. [SanPiN 2.6.1.1192-03. Hygienic Requirements for Design and Operation of X-ray Rooms, Scanners and X-ray examinations].
14. Safontsev I.P. et al. The role of screening in lung cancer control in Krasnoyarsk Region. Voprosy Onkologii, 2017, vol. 63, no. 3, pp. 385-393. (In Russ.)
15. AAPM Position Statement on Radiation Risks from Medical Imaging Procedures 4.10.2018 Available: https://www.aapm.org/org/policies/details.asp?id=318&type=PP¤t=true&fbclid=IwAR0PvhjyjBCC-rYkxVwjfpM5h1Pcasy8zfPaC3RTQJD7KBOntinBwoecQVc (Accessed 04.06.2019)
16. Aberle D.R. et al. National lung screening trial. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med., 2011, vol. 365, pp. 395-409.
17. American Association of Physicists in Medicine et al. Lung cancer screening CT protocols, version 4.0. 2016.
18. Bach P.B. et al. Benefits and Harms of CT Screening for Lung Cancer. JAMA, 2012, vol. 30, no. 22, pp. 2418.
19. Baldwin D.R., Callister M.E.J. The British Thoracic Society guidelines on the investigation and management of pulmonary nodules. Thorax, 2015, vol. 70, no. 8, pp. 794-798.
20. Becker N. et al. Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round. J. Cancer Res. Clin. Oncol., 2012, vol. 138, no. 9, pp. 1475-1486.
21. Blanchon T. et al. Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer, 2007, vol. 58, no. 1, pp. 50-58.
22. Brain K. et al. Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial. Thorax, 2016, vol. 71, no. 11, pp. 996-1005.
23. Bray F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2018, vol. 68, no. 6, pp. 394-424.
24. Buckens C.F. et al. Osteoporosis markers on low-dose lung cancer screening chest computed tomography scans predict all-cause mortality. Eur. Radiology, 2014, vol. 25, no. 1, pp. 132-139.
25. Cagnon C.H. et al. Description and implementation of a quality control program in an imaging-based clinical trial. Academ. Radiol., 2006, vol. 13, no. 11, pp. 1431-1441.
26. Cruz C.S.D., Tanoue L.T., Matthay R.A. Lung cancer: epidemiology, etiology, and prevention. Clin. Chest Med., 2011, vol. 32, no. 4, pp. 605-644.
27. Detterbeck F.C. et al. The eighth edition lung cancer stage classification. Chest, 2017, vol. 151, no. 1, pp. 193-203.
28. Gierada D.S. et al. CT quality assurance in the lung screening study component of the National Lung Screening Trial: implications for multicenter imaging trials. Am. J. Roentgenol., 2009, vol. 193, no. 2, pp. 419-424.
29. Gohagan J.K. et al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer, 2005, vol. 47, no. 1, pp. 9-15.
30. Gohagan J.K. et al. The prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute. Cancer, 1995, vol. 75, no. S7, pp. 1869-1873.
31. Gordic S. et al. Ultralow-dose chest computed tomography for pulmonary nodule detection: first performance evaluation of single energy scanning with spectral shaping. Investigative Radiol., 2014, vol. 49, no. 7, pp. 465-473.
32. Heuvelmans M.A. et al. Disagreement of diameter and volume measurements for pulmonary nodule size estimation in CT lung cancer screening. Thorax, 2018, vol. 73, no. 8, pp. 779-781.
33. Hoffman R.M., Sanchez R. Lung cancer screening. Med. Clin. North Amer., 2017, vol. 101, no. 4, pp. 769-785.
34. Horeweg N. et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol., 2014, vol. 15, no. 12, pp. 1332-1341.
35. IInfante M. et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am. J. Respir. Crit. Care Med., 2009, vol. 180, no. 5, pp. 445-453.
36. International Commission on Radiological Protection (ICRP) Guidance for Occupational Exposure. (Available: https://www.remm.nlm.gov/ICRP_guidelines.htm Accessed 04.06.2019).
37. Li K. et al. Selecting high-risk individuals for lung cancer screening: a prospective evaluation of existing risk models and eligibility criteria in the German EPIC cohort. Cancer Prevent. Res., 2015, vol. 8, no. 9, pp. 777-785.
38. Liu C.C. et al. Cost-effectiveness of lung cancer screening worldwide: a systematic review. Zhonghua Liu Xing Bing Xue Za Zhi=Zhonghua Liuxingbingxue Zazhi, 2019, vol. 40, no. 2, pp. 218-226.
39. Lung-RADS™ Version 1.0 Assessment Categories. Release date: April 28, 2014. Available: https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/LungRADS_AssessmentCategories.pdf?la=en Accessed 04.06.2019.
40. Lynch D.A. et al. CT-based visual classification of emphysema: association with mortality in the COPDGene study. Radiology, 2018, vol. 288, no. 3, pp. 859-866.
41. MacMahon H. et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology, 2017, vol. 284, no. 1, pp. 228-243.
42. Macri F. et al. Value of ultra-low-dose chest CT with iterative reconstruction for selected emergency room patients with acute dyspnea. Eur. J. Radiol., 2016, vol. 85, no. 9, pp. 1637-1644.
43. Martin M.D. et al. Lung-RADS: pushing the limits. Radiographics, 2017, vol. 37, no. 7, pp. 1975-1993.
44. McClelland R.L. et al. Distribution of coronary artery calcium by race, gender, and age. Circulation, 2006, vol. 113, no. 1, pp. 30-37.
45. McWilliams A. et al. Probability of cancer in pulmonary nodules detected on first screening CT. New Engl. J. Med., 2013, vol. 369, no. 10, pp. 910-919.
46. Meier-Schroers M. et al. Lung cancer screening with MRI: results of the first screening round. J. Cancer Res. Clin. Oncol., 2018, vol. 144, no. 1, pp. 117-125.
47. Mets O.M. et al. Diagnosis of chronic obstructive pulmonary disease in lung cancer screening Computed Tomography scans: independent contribution of emphysema, air trapping and bronchial wall thickening. Respir. Res., 2013, vol. 14, no. 1, pp. 59.
48. Mets O.M. et al. Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans. Jama, 2011, vol. 306, no. 16, pp. 1775-1781.
49. Nawa T. et al. A population-based cohort study to evaluate the effectiveness of lung cancer screening using low-dose CT in Hitachi city, Japan. Japanese J. Clin. Oncol., 2018, vol. 49, no. 2, pp. 130-136.
50. NCCN guidelines version 2.2019 Lung cancer screening Available: https://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf Accessed 04.06.2019.
51. Oudkerk M. et al. European position statement on lung cancer screening. Lancet Oncol., 2017, vol. 18, no. 12, pp. e754-e766.
52. Pastorino U. et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur. J. Cancer Prevention, 2012, vol. 21, no. 3, pp. 308-315.
53. Pastorino U. et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann. Oncol., 2019.
54. Pegna A.L. et al. Four-year results of low-dose CT screening and nodule management in the ITALUNG trial. J. Thoracic Oncol., 2013, vol. 8, no. 7, pp. 866-875.
55. Program in Epidemiology of Chronic Pulmonary Diseases. 2018. Available: http://www.cumc.columbia.edu/dept/medicine/generalmed/epi_lung.htm. Accessed 9 July 2018.
56. Radiological Society of North America. Radiology info for patients. Available: .www.radiologyinfo.org. Accessed August 22, 2013.
57. Sanchez-Salcedo P. et al. Improving selection criteria for lung cancer screening. The potential role of emphysema. Am. J. Respir. Crit. Care Med., 2015, vol. 191, no. 8, pp. 924-931.
58. Shen H. Low-dose CT for lung cancer screening: opportunities and challenges. Frontiers of Medicine, 2017, vol. 12, no. 1, pp. 116-121.
59. Sozzi G. et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J. Clin. Oncol., 2014, vol. 32, no. 8, pp. 768.
60. Spearman J.V. et al. Prognostic value of epicardial fat volume measurements by computed tomography: a systematic review of the literature. Eur. Radiol., 2015, vol. 25, no. 11, pp. 3372-3381.
61. Takahashi E.A. et al. Prospective pilot evaluation of radiologists and computer-aided pulmonary nodule detection on ultra-low-dose CT with tin filtration. J. Thoracic Imaging, 2018, vol. 33, no. 6, pp. 396-401.
62. ten Haaf K. et al. Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a population-based setting: a microsimulation modeling analysis in Ontario, Canada. PLos Med., 2017, vol. 14, no. 2, pp. E1002225.
63. Terzi A. et al. Lung cancer detection with digital chest tomosynthesis: baseline results from the observational study SOS. J. Thoracic Oncol., 2013, vol. 8, no. 6, pp. 685-692.
64. The top 10 causes of death. WHO, 2018. Available: http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 4 July 2018.
65. US Preventive Services Task Force. Final Update Summary: Lung Cancer: Screening. 2015. Available: http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening (accessed July 26, 2017).
66. Veronesi G. et al. Computed tomography screening for lung cancer: results of ten years of annual screening and validation of cosmos prediction model. Lung Cancer, 2013, vol. 82, no. 3, pp. 426-430.
67. Wille M.M.W. et al. Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. Am. J. Respir. Crit. Care Med., 2016, vol. 193, no. 5, pp. 542-551.
68. Woo K.M. et al. Surrogate markers and the association of low-dose CT lung cancer screening with mortality. JAMA Oncology, 2018, vol. 4, no. 7, pp. 1006.
69. Wood D.E. et al. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J. National Comprehensive Cancer Network, 2018, vol. 16, no. 4, pp. 412-441.
70. Xia C. et al. Early imaging biomarkers of lung cancer, COPD and coronary artery disease in the general population: rationale and design of the ImaLife (Imaging in Lifelines) Study. Eur. J. Epidemiol., 2019.
71. You C. et al. Structurally-sensitive multi-scale deep neural network for low-dose CT denoising. IEEE Access, 2018, vol. 6, pp. 41839-41855.
72. Yousaf-Khan U. et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax, 2017, vol. 72, no. 1, pp. 48-56.
Review
For citations:
Gombolevskiy V.A., Chernina V.Yu., Blokhin I.A., Nikolaev A.E., Barchuk A.A., Morozov S.P. Main achievements of low-dose computed tomography in lung cancer screening. Tuberculosis and Lung Diseases. 2021;99(1):61-70. (In Russ.) https://doi.org/10.21292/2075-1230-2021-99-1-61-70
Views:
2685
Email this article 